The reintroduction of nonleukoreduced blood: Would patients and clinicians agree?

Lizabeth Rosenbaum, Peter Tomasulo, Karen Shoos Lipton, Paul Ness

Research output: Contribution to journalReview articlepeer-review


Universal leukoreduction is a cornerstone of modern, high-quality transfusion therapy and a reasonable means to avert the consequences of failing to identify those who currently need leukoreduced products and those who will need these products but have not yet been identified. It should be considered best practice to provide leukoreduced blood to all patients, removing any risk that a patient will be harmed if nonleukoreduced blood is stored and subsequently transfused inappropriately. Given the numerous studies that support leukoreduction as a means to decrease current and future risks to patients, it is troubling to introduce nonleukoreduced blood components as a measure to control costs. Before leukoreduction was universal, there was debate about which indications for leukoreduced productswere the strongest and whichwere most cost-effective. Now that leukoreduction is nearly universal and patients are experiencing its benefits, the reintroduction of nonleukoreduced blood forces the discussion about which patient groups should be exposed to the higher risks of receiving nonleukoreduced components.

Original languageEnglish (US)
Pages (from-to)2739-2743
Number of pages5
Issue number12
StatePublished - Dec 2011

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology


Dive into the research topics of 'The reintroduction of nonleukoreduced blood: Would patients and clinicians agree?'. Together they form a unique fingerprint.

Cite this